drugset / Trial / NCT00061880
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
Open-labelTreatment
Summary
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.
Timeline
- Start
- 2003-02
- Primary completion
- 2005-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | forodesine | Small molecule | — | Intravenous |